ES2252205T3 - Nueva forma cristalina derivada de un pirrolidiltiocarbapenem. - Google Patents

Nueva forma cristalina derivada de un pirrolidiltiocarbapenem.

Info

Publication number: ES2252205T3
Authority: ES; Spain
Prior art keywords: crystal; type; methyl; diffraction; hydroxyethyl
Prior art date: 2000-03-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01917764T

Other languages

English (en)

Spanish (es)

Inventor

Izumi C/O Shionogi & Co. Ltd. Saitoh

Masayuki C/O Shionogi & Co. Ltd. Takahira

Toshio C/O Shionogi & Co. Ltd. Kawakita

Yasuyuki C/O Shionogi & Co. Ltd. Yoshioka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shionogi and Co Ltd

Original Assignee

Shionogi and Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-03-30

Publication date

2006-05-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18614158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2252205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-30 Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd

2006-05-16 Application granted granted Critical

2006-05-16 Publication of ES2252205T3 publication Critical patent/ES2252205T3/es

2021-03-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000013078 crystal Substances 0.000 claims abstract description 152
-1 sulfamoylaminomethyl Chemical group 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 16
238000002441 X-ray diffraction Methods 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
239000011521 glass Substances 0.000 claims description 13
239000000843 powder Substances 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 7
FYZUENZXIZCLAZ-UHFFFAOYSA-N 2-methylhept-2-enoic acid Chemical compound CCCCC=C(C)C(O)=O FYZUENZXIZCLAZ-UHFFFAOYSA-N 0.000 claims description 5
238000011049 filling Methods 0.000 claims description 5
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 3
239000000243 solution Substances 0.000 description 18
238000003860 storage Methods 0.000 description 18
238000001035 drying Methods 0.000 description 15
238000005259 measurement Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 10
XLJMOHKQRRPBDS-IENPIDJESA-N (5S)-4-pyrrolidin-1-ylsulfanyl-1-azabicyclo[3.2.0]hept-2-en-7-one Chemical compound N1(CCCC1)SC1C=CN2[C@H]1CC2=O XLJMOHKQRRPBDS-IENPIDJESA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000000634 powder X-ray diffraction Methods 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
150000004683 dihydrates Chemical class 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000011125 type II (treated soda lime glass) Substances 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
230000000845 anti-microbial effect Effects 0.000 description 4
239000000428 dust Substances 0.000 description 4
150000004682 monohydrates Chemical class 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
238000012360 testing method Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000012488 sample solution Substances 0.000 description 3
239000012086 standard solution Substances 0.000 description 3
239000011124 type III (regular soda lime glass) Substances 0.000 description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N 4-hydroxyproline Chemical compound OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical class C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000000151 deposition Methods 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000011126 type IV (general purpose soda lime glass) Substances 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000003781 beta lactamase inhibitor Substances 0.000 description 1
229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000004927 clay Substances 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000012812 general test Methods 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000000411 inducer Substances 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
229940073769 methyl oleate Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
LEGILXNWHFHFQF-UHFFFAOYSA-N octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O LEGILXNWHFHFQF-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000013097 stability assessment Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000006097 ultraviolet radiation absorber Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

ES01917764T 2000-03-31 2001-03-30 Nueva forma cristalina derivada de un pirrolidiltiocarbapenem. Expired - Lifetime ES2252205T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000099868		2000-03-31
JP2000-99868		2000-03-31

Publications (1)

Publication Number	Publication Date
ES2252205T3 true ES2252205T3 (es)	2006-05-16

Family

ID=18614158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES01917764T Expired - Lifetime ES2252205T3 (es)	2000-03-31	2001-03-30	Nueva forma cristalina derivada de un pirrolidiltiocarbapenem.

Country Status (17)

Country	Link
US (5)	US20030153191A1 (2)
EP (1)	EP1270575B1 (2)
JP (1)	JP3375084B2 (2)
KR (1)	KR100472842B1 (2)
CN (1)	CN1192030C (2)
AT (1)	ATE304014T1 (2)
AU (2)	AU2001244692B2 (2)
BR (1)	BRPI0109712B8 (2)
CA (1)	CA2404703C (2)
CY (2)	CY1105674T1 (2)
DE (1)	DE60113243T2 (2)
DK (1)	DK1270575T3 (2)
ES (1)	ES2252205T3 (2)
MX (1)	MXPA02009592A (2)
TW (1)	TWI293631B (2)
WO (1)	WO2001072750A1 (2)
ZA (1)	ZA200207675B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001244692B2 (en) *	2000-03-31	2004-10-14	Shionogi & Co., Ltd.	Novel crystal form of pyrrolidylthiocarbapenem derivative
JP5004355B2 (ja) *	2001-05-10	2012-08-22	塩野義製薬株式会社	アセチルチオピロリジン誘導体の製法
CA2467427A1 (en) *	2001-11-16	2003-05-22	Ranbaxy Laboratories Limited	Process for the preparation of crystalline imipenem
TWI353855B (en)	2005-05-26	2011-12-11	Shionogi & Co	Method for preparing an aqueous solution of doripe
EP2014666A4 (en) *	2006-04-28	2011-06-01	Kaneka Corp	IMPROVED PROCESS FOR CRYSTALLIZING INTERMEDIATES OF CARBAPENEMIC ANTIBIOTICS
WO2008006298A1 (en) *	2006-07-03	2008-01-17	Chengdu Di'ao Jiuhong Pharmaceutical Factory	Novel crystal form of doripenem, preparation method and uses thereof
CN101191787B (zh) *	2006-11-21	2011-07-27	上海医药工业研究院	高效液相色谱法测定多利培南含量的方法
EP2276762B1 (en) *	2008-03-24	2014-10-01	Ranbaxy Laboratories Limited	Process for the preparation of sterile doripenem
CN103025733B (zh) *	2010-06-03	2015-11-25	山东轩竹医药科技有限公司	碳青霉烯类衍生物或其水合物的晶型及其制备方法与用途
CN102977101A (zh) *	2011-09-07	2013-03-20	中国人民解放军军事医学科学院毒物药物研究所	多尼培南一水合物、其药物组合物、其制备方法和用途
CN102285988B (zh) *	2011-09-08	2012-09-05	上海希迈医药科技有限公司	一种多尼培南水合物晶体及其制备方法
WO2013068910A1 (en) *	2011-11-08	2013-05-16	Ranbaxy Laboratories Limited	Process for the preparation of polymorphs of doripenem
CN104072497B (zh) *	2013-03-29	2017-10-03	石药集团中奇制药技术（石家庄）有限公司	一种多尼培南新结晶及其制备方法
CN103389347B (zh) *	2013-07-26	2015-12-09	深圳市海滨制药有限公司	高效液相色谱法测定多尼培南的方法
CN106255694A (zh) *	2014-04-28	2016-12-21	Jw制药公司	新型多尼培南晶体及其制备方法
KR20160007679A (ko)	2016-01-04	2016-01-20	제일약품주식회사	도리페넴의 신규한 결정형

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5317016A (en)	1991-08-20	1994-05-31	Shionogi Seiyaku Kabushiki Kaisha	Pyrrolidylthiocarbapenem derivative
US5539102A (en) *	1992-02-21	1996-07-23	Shionogi Seiyaku Kabushiki Kaisha	Production method for sulfamide
DE69528166T2 (de) *	1994-05-02	2003-04-30	Shionogi & Co., Ltd.	Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung
JP3558684B2 (ja) *	1994-06-28	2004-08-25	塩野義製薬株式会社	ピロリジルチオカルバペネム誘導体の乾燥方法
AU2001244692B2 (en) *	2000-03-31	2004-10-14	Shionogi & Co., Ltd.	Novel crystal form of pyrrolidylthiocarbapenem derivative
EP1595883A4 (en) *	2003-02-14	2008-11-26	Shionogi & Co	INTERMEDIATE PRODUCT CRYSTAL FOR CARBAPENEM
US20120035357A1 (en)	2009-02-26	2012-02-09	Orchid Chemicals & Pharmaceuticals Ltd.	Process for the preparation of carbapenem antibiotic

2001
- 2001-03-30 AU AU2001244692A patent/AU2001244692B2/en not_active Ceased
- 2001-03-30 WO PCT/JP2001/002834 patent/WO2001072750A1/ja not_active Ceased
- 2001-03-30 ES ES01917764T patent/ES2252205T3/es not_active Expired - Lifetime
- 2001-03-30 US US10/240,465 patent/US20030153191A1/en not_active Abandoned
- 2001-03-30 BR BRPI0109712-1 patent/BRPI0109712B8/pt not_active IP Right Cessation
- 2001-03-30 CN CNB01810309XA patent/CN1192030C/zh not_active Ceased
- 2001-03-30 KR KR10-2002-7012979A patent/KR100472842B1/ko not_active Expired - Lifetime
- 2001-03-30 TW TW090107676A patent/TWI293631B/zh not_active IP Right Cessation
- 2001-03-30 DK DK01917764T patent/DK1270575T3/da active
- 2001-03-30 MX MXPA02009592A patent/MXPA02009592A/es active IP Right Grant
- 2001-03-30 AT AT01917764T patent/ATE304014T1/de active
- 2001-03-30 AU AU4469201A patent/AU4469201A/xx active Pending
- 2001-03-30 CA CA002404703A patent/CA2404703C/en not_active Expired - Fee Related
- 2001-03-30 JP JP2001570660A patent/JP3375084B2/ja not_active Expired - Lifetime
- 2001-03-30 EP EP01917764A patent/EP1270575B1/en not_active Expired - Lifetime
- 2001-03-30 DE DE60113243T patent/DE60113243T2/de not_active Expired - Lifetime
2002
- 2002-09-25 ZA ZA200207675A patent/ZA200207675B/xx unknown
2005
- 2005-11-28 CY CY20051101453T patent/CY1105674T1/el unknown
2006
- 2006-11-10 US US11/595,348 patent/US20070060562A1/en not_active Abandoned
2008
- 2008-02-05 US US12/012,932 patent/US8247402B2/en not_active Expired - Fee Related
2009
- 2009-01-23 CY CY200900001C patent/CY2009001I1/el unknown
2012
- 2012-08-14 US US13/585,611 patent/US20130059831A1/en not_active Abandoned
2014
- 2014-02-21 US US14/187,010 patent/US9221823B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20130059831A1 (en)	2013-03-07
BR0109712A (pt)	2003-04-29
CN1192030C (zh)	2005-03-09
AU4469201A (en)	2001-10-08
DE60113243T2 (de)	2006-02-16
EP1270575A4 (en)	2004-02-18
ATE304014T1 (de)	2005-09-15
US9221823B2 (en)	2015-12-29
US20150031664A1 (en)	2015-01-29
US20080207586A1 (en)	2008-08-28
CY2009001I2 (el)	2009-11-04
BRPI0109712B1 (pt)	2017-10-24
US20070060562A1 (en)	2007-03-15
EP1270575B1 (en)	2005-09-07
DE60113243D1 (de)	2005-10-13
CN1432016A (zh)	2003-07-23
AU2001244692B2 (en)	2004-10-14
DK1270575T3 (da)	2006-01-16
WO2001072750A1 (en)	2001-10-04
BRPI0109712B8 (pt)	2021-05-25
TWI293631B (2)	2008-02-21
CY1105674T1 (el)	2010-07-28
CA2404703C (en)	2007-06-05
US20030153191A1 (en)	2003-08-14
KR100472842B1 (ko)	2005-03-10
KR20020087446A (ko)	2002-11-22
ZA200207675B (en)	2003-09-25
CA2404703A1 (en)	2002-09-26
MXPA02009592A (es)	2003-03-12
CY2009001I1 (el)	2009-11-04
EP1270575A1 (en)	2003-01-02
US8247402B2 (en)	2012-08-21
JP3375084B2 (ja)	2003-02-10

Publication	Publication Date	Title
ES2252205T3 (es)	2006-05-16	Nueva forma cristalina derivada de un pirrolidiltiocarbapenem.
CS214721B2 (en)	1982-05-28	Method of making the pentahydrate of +l6r,7r+p-7-+l+lz+p-2-+l2-aminothiazol-4-yl+p-2-+l2-carboxyprop-2-oxyimino+p acetamido+p-3-+l1-piridiniummethyl+pcef-3-em-4-carboxylate
AU758190B2 (en)	2003-03-20	Crystalline 1-methylcarbapenem compounds
JPWO2001072750A1 (ja)	2003-07-08	ピロリジルチオカルバペネム誘導体の新型結晶
EP0560613B1 (en)	1998-11-25	Antimicrobial carbapenem derivatives, their preparation and their therapeutic use
US8822445B2 (en)	2014-09-02	Crystalline form of carbapenem derivative or its hydrates and preparation methods and uses thereof
RU2090567C1 (ru)	1997-09-20	Кристаллический пивалоилоксиметил (ir, 5s, 6s)-[(4r)-2-оксо-4-пирролидинилтио]-6-[(ir)-1-гидроксиэтил]-1-метил-1-карбапен-2-ем-3-карбоксилат и способ его получения
US5068322A (en)	1991-11-26	Crystalline cephalosporin compounds
CN101100468A (zh)	2008-01-09	多利培南水合物结晶及其制备方法
JPS58188887A (ja)	1983-11-04	カルバペネム抗生物質
EP2186814A1 (en)	2010-05-19	Sulfonyl-substituted carbapenem compounds
CN101945873A (zh)	2011-01-12	β-内酰胺化合物的稳定结晶
KR20000057441A (ko)	2000-09-15	신규한 세펨 유도체
CN103497207B (zh)	2015-09-30	比阿培南b型结晶
JPH0764846B2 (ja)	1995-07-12	２−（置換ピロリジニルチオ）カルバペネム誘導体
JPH08113573A (ja)	1996-05-07	結晶性カルバペネム化合物
CZ2001277A3 (cs)	2001-05-16	Nové C2 S/O- a S/N-formaldehydacetalové deriváty karbapenem-3-karboxylových kyselin a jejich použití jako antibiotik a inhibitorů Blaktamáz
HK1011976B (en)	2000-03-24	Antimicrobial carbapenem derivatives, their preparation and their therapeutic use
JPH07109279A (ja)	1995-04-25	結晶性カルバペネム誘導体
JPH06211859A (ja)	1994-08-02	２−（２−置換ピロリジニルチオ）カルバペネム誘導体